GlassScriptPhysician profile
Misal M Patel
NPI 1164855714
$3,128.97
in general payments reported to CMS, 2019-2025
33 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.48 · 2020: $267 · 2021: $537 · 2022: $614 · 2023: $629 · 2024: $679 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,695.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $834.72 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $445.68 | 2021-2025 | |
| Pfizer INC. | $251.45 | 2021-2025 | |
| Abbott Laboratories | $191.57 | 2023-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $188.11 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $172.26 | 2020-2025 | Farxiga, Airsupra |
| Astellas Pharma US INC | $148.72 | 2021-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $108.42 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Boston Scientific Corporation | $84.86 | 2022-2024 | |
| Amgen INC. | $73.71 | 2020-2025 | Otezla, Repatha, Krystexxa |
| Glaxosmithkline, LLC. | $65.22 | 2021-2024 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $56.91 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $44.96 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $42.65 | 2024 | Spravato |
| Sanofi Pasteur INC. | $39.28 | 2021-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $38.90 | 2020-2021 | |
| Esperion Therapeutics, INC. | $33.85 | 2021 | |
| Idorsia Pharmaceuticals US INC | $31.50 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $29.40 | 2022 | |
| Mannkind Corporation | $26.87 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.19 | 2021 | |
| Amarin Pharma, INC. | $18.71 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.40 | 2021 | |
| Eisai INC. | $18.11 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.51 | 2025 | Caplyta |
| Ardelyx, INC. | $17.28 | 2024 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.31 | 2020 | |
| Gilead Sciences, INC. | $15.70 | 2020 | |
| Alexion Pharmaceuticals, INC. | $15.48 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.12 | 2021 | |
| Dexcom, INC. | $14.42 | 2024 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $14.08 | 2022 | |
| Nevro Corp. | $12.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.